Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Howard Hochster, MD, discusses the optimal duration of FOLFOX therapy in stage III colon cancer

Dr. Hochster, Associate Director for Clinical Services, Yale Cancer Center, on whether stage III colon cancer patients should be treated with 3 months of 6 months of FOLFOX therapy

Published: 08 June 2017

Recent Videos: Colorectal

video

Atrayee Basu Mallick, MD, shares highlights from the 2018 ASCO Annual Meeting

Dr. Mallick discusses some of the advances in the treatment of colorectal cancer coming out of the 2018 ASCO Annual ...

video

Atrayee Basu Mallick, MD, considers how tumor-sidedness impacts CRC treatment algorithms

Dr. Mallick explains how tumor-sidedness impacts her colorectal cancer (CRC) treatment algorithms

video

Atrayee Basu Mallick, MD, discusses how nivolumab is incorporated into mCRC treatment algorithms

Dr. Mallick tells us how nivolumab is being incorporated into metastatic colorectal cancer (mCRC) treatment algorithms

video

Atrayee Basu Mallick, MD, tells us about the outcomes of the Checkmate 142 study in mCRC

Dr. Mallick comments on the outcomes of the Checkmate 142 study looking ipilimumab and nivolumab in metastatic colorectal cancer (mCRC) ...

video

Atrayee Basu Mallick, MD, on the addition of vemurafenib to the NCCN guidelines for mCRC

Dr. Mallick elaborates on the patient type and setting where vemurafenib has been added to the NCCN guidelines for metastatic ...

video

Atrayee Basu Mallick, MD, regarding the impact of stage & mismatch repair status on CRC treatment

Dr. Mallick explains how the stage of colorectal cancer (CRC) and the mismatch repair status impact treatment algorithms

video

Atrayee Basu Mallick, MD, offers opinion on immunotherapy in colorectal cancer

Dr. Mallick shares her thoughts on the headline “Immunotherapy Now Standard for Some Patients With Colorectal Cancer”

video

John Leighton, MD, on the headline “Immunotherapy Now Standard for Some Patients With CRC”

Dr. Leighton offers opinion on the headline “Immunotherapy Now Standard for Some Patients With Colorectal Cancer” coming out of the ...

video

John Leighton, MD, explains how tumor sidedness impacts CRC treatment algorithms

Dr. Leighton discusses whether tumor sidedness impacts colorectal cancer treatment algorithms

video

John Leighton, MD, comments on the outcomes of Checkmate 142 in mCRC

Dr. Leighton elaborates on the outcomes of the Checkmate 142 study examining ipilimumab and nivolumab in metastatic colorectal cancer (mCRC) ...

Related Videos

video-image

Atrayee Basu Mallick, MD, shares highlights from the 2018 ASCO Annual Meeting

video-image

Atrayee Basu Mallick, MD, considers how tumor-sidedness impacts CRC treatment algorithms

video-image

Atrayee Basu Mallick, MD, discusses how nivolumab is incorporated into mCRC treatment algorithms

video-image

Atrayee Basu Mallick, MD, tells us about the outcomes of the Checkmate 142 study in mCRC

video-image

Atrayee Basu Mallick, MD, on the addition of vemurafenib to the NCCN guidelines for mCRC

video-image

Atrayee Basu Mallick, MD, regarding the impact of stage & mismatch repair status on CRC treatment

video-image

Atrayee Basu Mallick, MD, offers opinion on immunotherapy in colorectal cancer

video-image

John Leighton, MD, on the headline “Immunotherapy Now Standard for Some Patients With CRC”

video-image

John Leighton, MD, explains how tumor sidedness impacts CRC treatment algorithms

video-image

John Leighton, MD, comments on the outcomes of Checkmate 142 in mCRC

video-image

Howard Hochster, MD, regarding the outcomes of the PRODIGY7 study in mCRC

video-image

Howard Hochster, MD, comments on the VALENTINO study presented at ASCO 2018

video-image

Howard Hochster, MD, tells us about the outcomes of ECOG-7208 in 2nd line mCRC

video-image

Richard Goldberg, MD, on the headline, "Immunotherapy Now Standard for Some Patients With CRC"

video-image

Richard Goldberg, MD, elaborates on the outcomes of the PRODIGY7 study in mCRC patients

video-image

Al Benson III, MD, FACP, on how tumor-sidedness impacts colorectal cancer treatment algorithms

video-image

Al Benson III, MD, FACP, discusses the role of I-O and immunotherapy combinations when treating CRC

video-image

Al Benson, MD, on what molecular markers are most important to test for when treating CRC patients

video-image

Steven J. Cohen, MD, outlines the results of the Checkmate 142 study in mCRC patients

video-image

Steven J. Cohen, MD, discusses vemurafenib and the NCCN guidelines for mCRC patients

video-image

Steven J. Cohen, MD, provides insight into sequencing and efficacy outcomes in 2nd line mCRC

video-image

Steven J. Cohen, MD, describes how tumor sidedness impacts treatment decisions in mCRC

video-image

Steven J. Cohen, MD, regarding combination atezolizumab + cobimetinib in mCRC patients

video-image

Steven J. Cohen, MD, considers the improvement in duration of therapy examined in the ReDOS study

video-image

Steven J. Cohen, MD, on how to dose patients receiving regorafenib as a result of the ReDOS study

video-image

Philip Philip, MD, PhD, FRCP, discusses the impact of the Checkmate 142 study on mCRC

video-image

Richard Kim, MD, offers opinion on the ReDOS study and dose escalation of regorafenib

video-image

Scott Kopetz, MD, PhD, FACP, on the potential of binimetinib + immunotherapy in mCRC patients

video-image

Scott Kopetz, MD, PhD, FACP, regarding molecular profile matching in trials with mCRC patients

video-image

Scott Kopetz, MD, PhD, FACP, on the implications of the BEACON Phase 3 study in BRAF-mutant mCRC

video-image

Jeffrey Meyerhardt, MD, MPH, on dose escalation of regorafenib as a result of the ReDOS study

video-image

Jeffrey Meyerhardt, MD, MPH, discusses the length of adjuvant therapy for colorectal cancer patients

video-image

Jeffrey Meyerhardt, MD, MPH, on the implications of the BEACON Phase 3 study in BRAF-mutant mCRC

video-image

Jeffrey Meyerhardt, MD, MPH, considers the addition of vemurafenib to the NCCN guidelines for mCRC

video-image

Scott Kopetz, MD, PhD, FACP, explains how nivolumab is being incorporated into mCRC treatment

video-image

Scott Kopetz, MD, PhD, FACP, tells us about the outcomes of Checkmate 142 in mCRC patients

video-image

Scott Kopetz, MD, PhD, FACP, considers the addition of vemurafenib to the NCCN guidelines for mCRC

video-image

Scott Kopetz, MD, PhD, FACP, discusses the incidence of BRAF mutation in CRC patients

video-image

Howard Hochster, MD, outlines the results of the Checkmate 142 study in mCRC patients

video-image

Howard Hochster, MD, considers patient age and the OncotypeDX recurrence score in CRC

video-image

Alan Venook, MD, considers how immunotherapy is being integrated into CRC treatment algorithms

video-image

Alan Venook, MD, on the impact of dose escalation of regorafenib in mCRC patients

video-image

Alan Venook, MD, discusses vemurafenib and the NCCN guidelines for mCRC patients

video-image

Alan Venook, MD, explains how tumor sidedness affects therapeutic choice

video-image

Howard Hochster, MD, elaborates on how tumor sidedness affects therapeutic choice in mCRC patients

video-image

Howard Hochster, MD, on the ReDOS study, regorafenib, and the importance of duration of therapy

video-image

Howard Hochster, MD, offers opinion on the ReDOS study and dose escalation of regorafenib

video-image

Will Tomorrow's CAR-T Therapy Innovations Solve Today's Challenges?

video-image

How Can Manufacturers Help Institutions Prepare for CAR-T Therapies?

video-image

How Can a CAR-T Center Get Established and Effectively Treat Patients?

video-image

Sai-Hong Ignatius Ou, MD, PhD, comments on Tumor Mutation Burden (TMB) as a biomarker in NSCLC

video-image

Sai-Hong Ignatius Ou, MD, PhD, on pemetrexed maintenance therapy

video-image

Sai-Hong Ignatius Ou, MD, PhD, discusses key takeaways from the IMpower150 study at ASCO 2018

video-image

Sai-Hong Ignatius Ou, MD, PhD, comments on combo chemotherapy & immunotherapy in 2nd line NSCLC

video-image

Sai-Hong Ignatius Ou, MD, PhD, regarding combo chemotherapy & immunotherapy in 1st line NSCLC

video-image

Sai-Hong Ignatius Ou, MD, PhD, on testing for PD-L1 expression in NSCLC

video-image

Benjamin Philip Levy, MD, on Tumor Mutation Burden (TMB) as a biomarker in NSCLC

video-image

Benjamin Philip Levy, MD, on maintenance therapy following carboplatin, pemetrexed & pembrolizumab

video-image

Benjamin Philip Levy, MD, comments on the IMpower150 clinical trial in NSCLC

video-image

Benjamin Philip Levy, MD, on options for NSCLC patients who progress on 1st line I-O & chemotherapy

video-image

Benjamin Philip Levy, MD, regarding combo chemotherapy & immunotherapy in 2nd line NSCLC

video-image

Benjamin Philip Levy, MD, discusses the practice-changing outcomes from Keynote 189

video-image

Benjamin Philip Levy, MD, offers opinion on testing for PD-L1 expression in NSCLC

video-image

Novel Endpoints: Working Through Today's Challenges to Improve the Future of Cancer Care

video-image

Novel Endpoints in Cancer Care: What Lies Ahead

video-image

Oncology Clinical Trials: Why We're Searching for Emerging Endpoints

video-image

Howard (Jack) West, MD, regarding Tumor Mutation Burden (TMB) as a biomarker for NSCLC patients

video-image

Howard (Jack) West, MD, on maintenance therapy after carboplatin, pemetrexed & pembrolizimab

video-image

NGS and Cancer: Combatting the Hazards of Misinformation

video-image

Will NGS-Based Cancer Tests Become Routine?

video-image

Next-Gen Sequencing is Transforming Oncology Practices

video-image

Howard (Jack) West, MD, discusses key takeaways from the IMpower150 study in NSCLC

video-image

Howard (Jack) West, MD, on treatment options for patients who progress on I-O & chemotherapy

video-image

Howard (Jack) West, MD, regarding the combination of immunotherapy & chemotherapy in NSCLC

video-image

Howard (Jack) West, MD, regarding PDL-1 expression and NSCLC

video-image

Howard A. "Skip" Burris III, MD, FACP, FASCO, considers predictive biomarkers in NSCLC

video-image

Howard A. "Skip" Burris III, MD, FACP, FASCO, comments on the TAILORx study from ASCO 2018

video-image

Howard A. "Skip" Burris III, MD, FACP, FASCO, on the outcomes of the PERSEPHONE clinical trial

video-image

Howard A. "Skip" Burris III, MD, FACP, FASCO, regarding novel concepts in clinical trial design

video-image

Howard A. "Skip" Burris III, MD, FACP, FASCO, shares his goals for the 2019 ASCO Annual Meeting

video-image

Neelima Denduluri, MD, on the outcomes of the SANDPIPER study presented at ASCO 2018

video-image

Neelima Denduluri, MD, looks back on the Short-HER trial from the 2017 ASCO Annual Meeting

video-image

Neelima Denduluri, MD, offers opinion on the PERSEPHONE trial in early HER2+ breast cancer

video-image

Neelima Denduluri, MD, tells us about the recent updates to breast cancer guidelines

video-image

Neelima Denduluri, MD, comments on the role of CDK4/6 inhibitors

video-image

Neelima Denduluri, MD, regarding the implications of the TAILORx study from ASCO 2018

video-image

Robert A. Figlin, MD, on the convenience factor of oral TKIs & treatment decisions in advanced RCC

video-image

Robert A. Figlin, MD, on the trade-offs between safety & efficacy when discussing 1st line RCC

video-image

Robert A. Figlin, MD, provides perspective on I-O failures

video-image

Robert A. Figlin, MD, on deciding which metastatic RCC patients should get a TKI as 1st line therapy

video-image

Robert A. Figlin, MD, on how checkpoint inhibitors figure into treatment for 1st line RCC patients

video-image

Walter Stadler, MD, on therapies for high-volume, metastatic castration-resistant prostate cancer

video-image

Walter Stadler, MD, on immunotherapy and prostate cancer treatment algorithms

video-image

Walter Stadler, MD, comments on the PROSPER & SPARTAN studies in prostate cancer

video-image

Walter Stadler, MD, regarding TKIs in the treatment of renal cell carcinoma

video-image

Walter Stadler, MD, on treating RCC in the 2nd line setting following I-O failure

video-image

Walter Stadler, MD, considers which mRCC patients should receive a TKI as 1st line therapy

video-image

David I. Quinn, MD, provides perspective on the trade-offs between safety & efficacy in 1st line RCC

video-image

David I. Quinn, MD, considers whether the convenience of oral TKIs impacts RCC treatment

video-image

David I. Quinn, MD, comments on 2nd line therapy options following I-O failure

video-image

David I. Quinn, MD, shares thoughts on Keynote 427 from the 2018 ASCO Annual Meeting

video-image

David I. Quinn, MD, regarding the most exciting RCC data coming out of ASCO 2018

video-image

Jeanny B. Aragon-Ching, MD, FACP, shares how checkpoint inhibitors fit into RCC treatment algorithms

video-image

Jeanny B. Aragon-Ching, MD, FACP, comments on 2nd line treatment options in RCC after I-O failure

video-image

Jeanny B. Aragon-Ching, MD, FACP, on response rates for erdafitinib in metastatic bladder cancer

video-image

Jeanny B. Aragon-Ching, MD, FACP, on molecular markers in high-risk muscle-invasive bladder cancer

video-image

Jeanny B. Aragon-Ching, MD, FACP, discusses new guidelines in treatment of metastatic bladder cancer

video-image

Jeanny B. Aragon-Ching, MD, FACP, regarding the impact of the PROSPER and SPARTAN clinical trials

video-image

Mohammad Jahanzeb, MD, FACP, discusses the significance of Keynote 42 from ASCO 2018

video-image

Mohammad Jahanzeb, MD, FACP, regarding pemetrexed maintenance therapy

video-image

Mohammad Jahanzeb, MD, FACP, on the results of Keynote 189, PDL-1 expression and patient selection

video-image

Eunice Wang, MD, tells us about the most exciting data coming out of the 2018 ASCO Annual Meeting

video-image

Eunice Wang, MD, on the role of nivolumab maintenance in high-risk AML patients

video-image

Eunice Wang, MD, regarding evolving treatment considerations for FLT3 mutated AML

video-image

Eunice Wang, MD, shares what we've learned about gilteritinib since the 2017 ASCO Annual Meeting

video-image

Eunice Wang, MD, considers the potential impact of gilteritinib in patients with FLT3-ITD AML

video-image

Eunice Wang, MD, on next-generation sequencing and treatment selection in AML

video-image

Neelima Denduluri, MD, speculates on the implications of taselisib data at ASCO 2018

video-image

Neelima Denduluri, MD, on the MONALEESA-3 study in HR+/HER2- advanced breast cancer

video-image

Neelima Denduluri, MD, considers whether the results of TAILORx are practice-changing

video-image

Gary D. Steinberg, MD, on whether FGFR inhibitors have the potential to be practice-changing

video-image

Bobby Green, MD, on next-generation sequencing and Flatiron's clinico-genomic database

video-image

Bobby Green, MD, shares an update on Flatiron’s clinico-genomic database

video-image

Bobby Green, MD, reflects on the 2018 ASCO Annual Meeting

video-image

Ghassan Abou-Alfa, MD, MBA, regarding the shortcomings of the RECIST study in HCC

video-image

Ghassan Abou-Alfa, MD, MBA, shares the outcomes of the CELESTIAL study from ASCO 2018

video-image

Ghassan Abou-Alfa, MD, MBA, considers how immunotherapies should be combined with TKIs

video-image

Ghassan Abou-Alfa, MD, MBA, on the latest in systemic therapy for advanced HCC

video-image

John Leighton, MD, regarding preoperative chemotherapy in resectable pancreatic cancer

video-image

John Leighton, MD, regarding the PA.6 clinical study presented at ASCO 2018

video-image

Primo N. Lara, Jr., MD, comments on which TKIs appear most effective in 1st line RCC

video-image

Primo N. Lara, Jr., MD, on whether the convenience of oral TKIs influences treatment decisions

video-image

Primo N. Lara, Jr., MD, considers the trade-offs between safety & efficacy in 1st line RCC treatment

video-image

Primo N. Lara, Jr., MD, regarding the treatment path following I-O failure

video-image

Primo N. Lara, Jr., MD, on deciding which mRCC patients should receive a TKI

video-image

Primo N. Lara, Jr., MD, on how checkpoint inhibitors fit into RCC treatment algorithms

video-image

Celestia S. Higano, MD, considers the role of immunotherapy in prostate cancer

video-image

Celestia S. Higano, MD, discusses outcomes from the PROSPER and SPARTAN studies at ASCO 2018

video-image

Edgardo S. Santos, MD, FACP, on the benefits of combination docetaxel + ramucirumab

video-image

Edgardo S. Santos, MD, FACP, regarding pemetrexed maintenance therapy

video-image

Edgardo S. Santos, MD, FACP, on the outcomes of Keynote 189 in metastatic NSCLC

video-image

Edgardo S. Santos, MD, FACP, discusses exciting developments out of ASCO 2018

video-image

Brian I. Rini, MD, FACP, comments on the CARMENA study presented at ASCO 2018

video-image

Brian I. Rini, MD, FACP, discusses the influence of the convenience of oral TKIs

video-image

Brian I. Rini, MD, FACP, regarding the trade-offs between safety & efficacy in 1st line RCC

video-image

Brian I. Rini, MD, FACP, considers 2nd line treatment in advanced RCC following I-O failure

video-image

Brian I. Rini, MD, FACP, on which metastatic RCC patients should receive a TKI as 1st line therapy

video-image

Brian I. Rini, MD, FACP, on how checkpoint inhibitors figure into treatment algorithms for RCC

video-image

James A. Posey III, MD, on the outcomes of the LAPACT study in locally advanced pancreatic cancer

video-image

James A. Posey III, MD, comments on the impact of immunotherapy agents in pancreatic cancer

video-image

James A. Posey III, MD, discusses the unmet medical needs in pancreatic ductal adenocarcinoma

video-image

James A. Posey III, MD, offers opinion on preoperative chemotherapy in resectable pancreatic cancer

video-image

James A. Posey III, MD, on the results and implications of the PA.6 clinical trial from ASCO 2018

video-image

Ivo Abraham, PhD, RN, comments on how we can demonstrate the value of cancer treatments

video-image

Ivo Abraham, PhD, RN, outlines biosimilar pricing and reimbursement

video-image

Ivo Abraham, PhD, RN, discusses those biosimilars that are approved or close to approval

video-image

Ivo Abraham, PhD, RN, speculates on the hurdles that could prevent the adoption of biosimilars

video-image

Ivo Abraham, PhD, RN, explains the key features of a biosimilar

video-image

Randall A. Oyer, MD, considers the work being done to address disparities in healthcare

video-image

Randall A. Oyer, MD, provides information on the ACCC Immuno-Oncology Institute

video-image

Randall A. Oyer, MD, explains how ACCC is interpreting the data on genetics presented at ASCO 2018

video-image

Roy S. Herbst, MD, PhD, discusses the benefits of using ramucirumab plus docetaxel in 2nd line NSCLC

video-image

Roy S. Herbst, MD, PhD, discusses drug sequencing as a result of Keynote 189 and 42 results

video-image

Roy S. Herbst, MD, PhD, on if patient selection will change as a result of Keynote 42

video-image

Roy S. Herbst, MD, PhD, on pemextrexed maintenance treatment

video-image

Roy S. Herbst, MD, PhD, shares what's exciting here at ASCO 2018

video-image

Roy S. Herbst, MD, PhD, on if Keynote 189 impacted view of PDL-1 expression and patient selection

video-image

Lisa Rometty on the collaboration between Watson and the VA Precision Oncology Program

video-image

Lisa Rometty shares some of the recent accomplishments of IBM's Watson

video-image

Lisa Rometty elaborates on Watson's role in clinical trial matching

video-image

Lisa Rometty regarding the impact of Watson on real-world evidence and clinical decision making

video-image

Lisa Rometty explains how augmented intelligence is helping oncologists better treat cancer patients

video-image

Julie Gralow, MD, speculates on taselisib as a standard of care based on the results of SANDPIPER

video-image

Julie Gralow, MD, tells us about the SANDPIPER proof of concept trial presented at ACSO 2018

video-image

Julie Gralow, MD, comments on the practice-changing implications of the TAILORx study

video-image

Julie Gralow, MD, discusses outcomes from the TAILORx study presented at ASCO 2018

video-image

Julie Gralow, MD, regarding the reduction in cardiac events in the PERSEPHONE study

video-image

Julie Gralow, MD, reflects on the PERSEPHONE trial from the 2018 ASCO Annual Meeting

video-image

Julie Gralow, MD, on the implications of the PERSEPHONE trial in early HER2+ breast cancer

video-image

Julie Gralow, MD, speaks to the significance of the MONALEESA-3 study

video-image

Julie Gralow, MD, elaborates on how to differentiate CDK4/6 inhibitors

video-image

Tomasz M. Beer, MD, on how immunotherapy is being integrated into CRPC treatment algorithms

video-image

Tomasz M. Beer, MD, on how the PROSPER and SPARTAN studies are impacting standard of care

video-image

Tomasz M. Beer, MD, discusses the latest trends in the multimodality treatment of prostate cancer

video-image

Tomasz M. Beer, MD, on how to avoid under-diagnosing and over-diagnosing prostate cancer

video-image

Tomasz M. Beer, MD, discusses the central themes regarding prostate cancer here at ASCO 2018

video-image

Mark Levis, MD, PhD, discusses exciting data from the 2018 ASCO Annual Meeting

video-image

Mark Levis, MD, PhD, speculates on evolving treatment considerations for FLT3 mutated AML

video-image

Mark Levis, MD, PhD, discusses what we've learned about gilteritinib in FLT3 mutated AML patients

video-image

Mark Levis, MD, PhD, comments on measurable residual disease in relapsed/refractory AML

video-image

Mark Levis, MD, PhD, on factors influencing 1st line therapy in AML patients with FLT3 mutations

video-image

Mark Levis, MD, PhD, regarding the impact of next-generation sequencing in AML

video-image

Nicholas J. Vogelzang, MD, on imaging as an effective solution for prostate cancer diagnosis

video-image

Nicholas J. Vogelzang, MD, offers opinion on how MRI has improved diagnosing in prostate cancer

video-image

Nicholas J. Vogelzang, MD, on how we can avoid under-diagnosing & over-diagnosing prostate cancer

video-image

Richard Goldberg, MD, on how the FIRE-3 data in CRC presented at ASCO 2018 reinforces CALGB 80405

video-image

Richard Goldberg, MD, considers the value of preoperative chemotherapy in pancreatic cancer

video-image

Richard Goldberg, MD, regarding the outcomes of the PA.6 clinical study in pancreatic cancer

video-image

Jennie Crews, MD, MMM, FACP, regarding key initiatives for the ACCC Immuno-Oncology Institute

video-image

Joan Schiller, MD, regarding Keynote trials from ASCO 2018 & the influence on choice of therapy

video-image

Joan Schiller, MD, considers the validity of Tumor Mutation Burden (TMB) as a biomarker

video-image

Joan Schiller, MD, on the impact of Keynotes 189 & 42 on drug sequencing regimens

video-image

Joan Schiller, MD, regarding the results of Keynote 42 presented at the 2018 ASCO Annual Meeting

video-image

Joan Schiller, MD, considers the continuation of pemetrexed maintenance

video-image

Joan Schiller, MD, offers her opinion on Keynote 189 & PDL-1 expression and patient selection

video-image

Jennie Crews, MD, MMM, FACP, outlines the mission of the ACCC Immuno-Oncology Institute

video-image

Douglas W. Blayney, MD, discusses the biggest takeaway regarding breast cancer here at ASCO 2018

video-image

Douglas W. Blayney, MD, on if the results of the TAILORx study practice changing

video-image

Douglas W. Blayney, MD, discusses the implications of the TAILORx study

video-image

Douglas W. Blayney, MD, discusses the MONALEESA-3 study in HR+/HER2- advanced breast cancer

video-image

Douglas W. Blayney, MD, on differentiating CDK4/6 Inhibitors and if they can be used interchangeably

video-image

Al Benson III, MD, FACP, tells us about the outcomes of the ECOG-ACRIN study

video-image

Jennie Crews, MD, MMM, FACP, on how community oncology is embracing biomarkers

video-image

Noa Biran, MD, on combination carfilzomib & daratumumab in revlimid-refractory multiple myeloma

video-image

Noa Biran, MD, considers whether VPd is effective in relapsed multiple myeloma

video-image

Noa Biran, MD, on the logistics involved in delivering CAR-T in the BB2121 study

video-image

Noa Biran, MD, on the impact of the BB2121 study in multiple myeloma

video-image

Noa Biran, MD, shares some of the exciting clinical advances presented at ASCO 2018

video-image

Sara M. Tolaney, MD, MPH on whether CDK4/6 inhibitors can be used interchangeably

video-image

Sara M. Tolaney, MD, MPH tells us about the outcomes of the MONARCH 2 study

video-image

David R. Gandara, MD, discusses drug sequencing as a result of Keynote 189 and 42 results

video-image

David R. Gandara, MD, on what will change about patient selection as a result of Keynote 42

video-image

David R. Gandara, MD, on continuing pemextrexed maintenance

video-image

David R. Gandara, MD, on whether Keynote 189 impacted view of PDL-1 expression and patient selection

video-image

David R. Gandara, MD, shares the benefits of using ramucirumab plus docetaxel in 2nd line NSCLC

video-image

David R. Gandara, MD, discusses exciting new developments in lung cancer here at ASCO 2018

video-image

Mohammad Jahanzeb, MD, FACP, discusses the impact of Keynote 189 & 42 on drug sequencing regimens

video-image

David I. Quinn, MD, on which metastatic RCC patients should receive a TKI as first-line therapy

video-image

Gary D. Steinberg, MD, discusses FGFR inhibitors in metastatic bladder cancer

video-image

Sara M. Tolaney, MD, MPH discusses the practice changing outcomes of the TAILORx study

video-image

Sara M. Tolaney, MD, MPH, discusses the fulvestrant + ribociclib arm of the MONALEESA-3 study

video-image

Sara M. Tolaney, MD, MPH, on whether the results of the TAILORx study are “practice changing”

video-image

Celestia S. Higano, MD, discusses new data being presented here at ASCO in metastatic CRPC

video-image

Celestia S. Higano, MD, discusses how MRI has improved the diagnosis of prostate cancer

video-image

Celestia S. Higano, MD, on imaging as a cost-effective solution for diagnosis of prostate cancer